Yahoo · Oct 2, 2026
These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
A few IBD 50 stocks are showing unusually narrow trading.
HN
NYSE · HNGE
Hinge Health, Inc.
Healthcare · Medical - Healthcare Information Services
$98.35
Up+$0.77 (+0.78%)
Updated Oct 7, 2026, 3:20 PM
SID Score
6.1/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 3.93B
- P/E ratio
- -7.38
- Dividend yield
- 0.00%
- 52-week range
- $34.64 – $99.81
- Volume
- 2.91M
- Avg. volume
- 1.62M
Price performance · HNGE
HNGE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
HNGE closed at $98.35 after 21 trading sessions, up 6.11% for the selected period.
- Last close
- $98.35
- Period change
- +6.11%
- Period low
- $88.26
- Period high
- $98.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $98.93 | $100.3599 | $96.0201 | $98.35 | 2.91M |
| Oct 5, 2026 | $99.00 | $99.805 | $97.363 | $98.35 | 3.18M |
| Oct 2, 2026 | $98.30 | $99.7296 | $96.95 | $97.67 | 975.35K |
| Oct 1, 2026 | $97.00 | $98.46 | $96.325 | $97.94 | 1.42M |
| Sep 30, 2026 | $95.52 | $98.4095 | $94.50 | $97.24 | 1.63M |
| Sep 29, 2026 | $94.20 | $97.9499 | $91.52 | $95.21 | 1.72M |
| Sep 28, 2026 | $93.98 | $94.155 | $91.76 | $92.45 | 1.28M |
| Sep 25, 2026 | $91.94 | $96.45 | $91.0332 | $95.57 | 1.09M |
| Sep 24, 2026 | $91.52 | $93.60 | $90.335 | $91.98 | 2.31M |
| Sep 23, 2026 | $93.63 | $94.28 | $89.75 | $92.28 | 1.7M |
| Sep 22, 2026 | $94.45 | $94.60 | $91.7801 | $94.15 | 1.33M |
| Sep 21, 2026 | $95.08 | $95.825 | $92.92 | $94.45 | 1.13M |
| Sep 18, 2026 | $95.39 | $96.26 | $92.60 | $94.90 | 4.87M |
| Sep 17, 2026 | $93.69 | $96.6599 | $93.655 | $94.72 | 2.06M |
| Sep 16, 2026 | $92.08 | $95.62 | $91.62 | $93.73 | 1.8M |
| Sep 15, 2026 | $94.73 | $95.50 | $92.36 | $92.39 | 1.16M |
| Sep 14, 2026 | $88.69 | $94.86 | $88.53 | $94.79 | 2.46M |
| Sep 11, 2026 | $89.50 | $90.808 | $86.2901 | $88.59 | 1.73M |
| Sep 10, 2026 | $89.00 | $91.76 | $86.78 | $88.26 | 2.42M |
| Sep 9, 2026 | $93.76 | $93.76 | $89.07 | $91.31 | 1.51M |
| Sep 8, 2026 | $91.88 | $93.50 | $90.075 | $92.69 | 2.2M |
Latest HNGE news
The latest Smart Investors Daily articles mentioning HNGE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HNGE research
Overview
Company profile and research snapshot.
Company profile
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients. The Company's clients are self-insured employers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $57.63
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | Needham | Buy | — |
| Sep 22, 2026 | Baird | Neutral | — |
| Sep 8, 2026 | Stifel | Buy | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 1, 2026
The 25-Year Stock Market Supercycle: Why The Biggest Acceleration Phase Is Still Ahead
Is a stock market supercycle underway? John Pocorobba breaks down how millennial demographics and AI could propel the market through 2035.
Benzinga · Sep 30, 2026
Needham Maintains Buy on Hinge Health, Raises Price Target to $115
Needham analyst Ryan MacDonald maintains Hinge Health (NYSE:HNGE) with a Buy and raises the price target from $97 to $115.
Yahoo · Sep 29, 2026
Hinge Health Growth Outlook Supported by Member Gains, New Products, BofA Says
Hinge Health's (HNGE) growth outlook is supported by "higher member participation," expansion of its
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
